We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Caspase-2 Drives Progression of Fatty Liver Disease

By LabMedica International staff writers
Posted on 25 Sep 2018
Print article
Image: A photomicrograph of a fibrotic liver section revealed by staining of collagen accumulation in a mouse with human-like NASH (Photo courtesy of the University of California, San Diego).
Image: A photomicrograph of a fibrotic liver section revealed by staining of collagen accumulation in a mouse with human-like NASH (Photo courtesy of the University of California, San Diego).
The enzyme caspase-2 has been shown to be critically linked to the progression of nonalcoholic fatty liver disease (NAFLD) to the more serious and aggressive nonalcoholic steatohepatitis (NASH) form of the syndrome.

NASH is the most aggressive form of non-alcoholic fatty liver disease, which includes a spectrum of chronic liver diseases and has become a leading cause of liver transplants. NAFLD progresses to NASH in response to elevated endoplasmic reticulum (ER) stress. While the onset of simple steatosis requires elevated de novo synthesis of lipids, progression to NASH is triggered by accumulation of hepatocyte-free cholesterol.

Investigators at the University of California San Diego (USA) reported in the September 13, 2018, online edition of the journal Cell that caspase-2, whose expression was found to be ER-stress inducible and elevated in human and mouse NASH, controlled the buildup of hepatic-free cholesterol and triglycerides by activating sterol regulatory element-binding proteins (SREBP).

Caspase-2 co-localized with site 1 protease (S1P) and cleaved it to generate a soluble active fragment that initiated SCAP (SREBP cleavage-activating protein)-independent SREBP1/2 activation in the ER. Elimination of caspase-2 or its pharmacological inhibition prevented diet-induced steatosis and NASH progression in ER-stress-prone mice.

"In NASH-free individuals, the activities of SREBP1 and SREBP2 are kept under control, which is essential for preventing excessive lipid accumulation in the liver," said senior author Dr. Michael Karin, professor of pharmacology at the University of California, San Diego. "However, in NASH patients, something goes awry and the liver continues to turn out excess amounts of triglycerides and cholesterol. This correlates with elevated SREBP1 and SREBP2 activities and increased caspase-2 expression. Our results show that caspase-2 is a critical mediator of NASH pathogenesis, not only in mice but probably in humans as well. While explaining how NASH is initiated, our findings also offer a simple and effective way to treat or prevent this devastating disease."

Related Links:
University of California San Diego

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more